Drug Trial Radar · NCT05281510
Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jun 9, 2022
Primary completion
Jan 16, 2025
Study completion Jan 16, 2025
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Mar 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goals of this clinical study are to learn more about the study drugs, VRC07-523LS, CAP256V2LS, and vesatolimod (VES) and how safe it is in women that have HIV and are on antiretroviral therapy (ART).
Conditions
- HIV-1-infection
Interventions
VesatolimodDrug
Administered orally
VRC07523LSBiological
Administered intravenously
CAP256V2LSBiological
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 61.1 weeks
- Percentage of Participants Experiencing Treatment-emergent Graded Laboratory AbnormalitiesTime frame: Up to 61.1 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
FRESH Clinical Research Site: Females Rising through Education, Support and Health
Umlazi, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.